DiaMedica Therapeutics Inc. DMAC
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +16.21%
- 1 year
- +32.14%
- Open
- 9.39
- Prev close
- 9.52
- Mkt cap
- 498.81M
- Vol
- 174.65K
- Avg vol
- 184.10K
- EPS
- -0.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.17
- High
- 9.54
- Forward P/E
- -7.26
- Beta
- 1.46
- Short ratio
- 3.88
- Inst. own
- 31.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 4.69
- 200-d avg
- 3.61
- 1y target
- 7.00
5D chart
Signals (111)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| RSI: Oversold | Oct 29, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 3 days ago |
| RSI: Overbought | Oct 28, 12:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 3 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:10 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 4 days ago |
| RSI: Oversold | Oct 27, 10:20 AM | 4 days ago |
| RSI: Oversold | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 11:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:00 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:35 AM | 5 days ago |
| RSI: Overbought | Oct 26, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 23, 3:25 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:20 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:10 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:05 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:00 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:55 PM | 1 week ago |
| RSI: Overbought | Oct 23, 12:45 PM | 1 week ago |
| SMA: Bullish | Oct 23, 11:40 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:25 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:35 AM | 1 week ago |
News
1 week ago gurufocus.com
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
-
1 week ago benzinga.com
DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-EstimationInterim Analysis Results Expected in Q1 2027
1 week ago businesswire.com
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
1 week ago businesswire.com
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
1 month ago businesswire.com
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
1 month ago gurufocus.com
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
1 month ago businesswire.com
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
2 months ago zacks.com
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is…
2 months ago zacks.com
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 months ago seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
2 months ago marketbeat.com
DiaMedica Therapeutics Q2 Earnings Call Highlights
DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the…
-
2 months ago benzinga.com
DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of…
2 months ago businesswire.com
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
2 months ago businesswire.com
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
3 months ago businesswire.com
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
4 months ago benzinga.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
4 months ago gurufocus.com
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction a
-
4 months ago benzinga.com
DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction
First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatmentDM199 is intended to improve maternal…
4 months ago businesswire.com
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute…
-
4 months ago benzinga.com
DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia
DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. investigational new drug (IND) application, provided…
4 months ago businesswire.com
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and…
5 months ago businesswire.com
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
-
5 months ago benzinga.com
DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim AnalysisInterim Analysis by Independent DSMB Expected to Determine if a Sample Size…
5 months ago businesswire.com
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and…
5 months ago businesswire.com
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
5 months ago seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
DiaMedica Therapeutics Q1 EPS $(0.19), Inline
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 5.56 percent decrease over losses of $(0.18) per share from the…
-
7 months ago benzinga.com
Earnings Scheduled For March 30, 2026
Earnings Scheduled For March 30, 2026
7 months ago benzinga.com
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.
-
8 months ago benzinga.com
DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke…
-
10 months ago benzinga.com
DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke…
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
11 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.
-
11 months ago benzinga.com
DiaMedica Therapeutics Q3 EPS $(0.17), Inline
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. This is a 13.33 percent decrease over losses of $(0.15) per share from…
-
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
11 months ago benzinga.com
An Overview of DiaMedica Therapeutics's Earnings
An Overview of DiaMedica Therapeutics's Earnings
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
-
1 year ago benzinga.com
DiaMedica Therapeutics Q2 EPS $(0.18) Beats $(0.19) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 38.46 percent decrease over losses…
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
-
1 year ago benzinga.com
Exploring DiaMedica Therapeutics's Earnings Expectations
Exploring DiaMedica Therapeutics's Earnings Expectations
-
1 year ago benzinga.com
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11
Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.
-
1 year ago benzinga.com
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14
Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $11 to $14.
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $12
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $10 to $12.
-
1 year ago benzinga.com
DiaMedica Therapeutics Announces Interim Results From Part 1a Of Phase 2 Study Of DM199 For Treatment Of Preeclampsia
Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central TimeDM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $10 price target.